Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Welch Allyn's portable ECG launches

This article was originally published in Clinica

Executive Summary

Welch Allyn is to address the telehealth market with the launch of a portable connectivity-ready electrocardiograph (ECG). The lightweight device, called the CP 50 ECG, is designed for use in settings where flexibility and efficiency are important. It can interface with the Welch Allyn CardioPerfect Workstation Software to connect patient data to electronic health records or a health information system, over the internet or through e-mail. The device comes with an integrated high-resolution thermal printer to generate ECG reports in customisable formats, and it also allows paperless archiving and flexible connectivity options. In addition, the CP 50 provides on-screen instructions that ensure accurate data capture by highlighting poor signals and connections. Welch Allyn said it is addressing the "growing demand" for products with greater efficiency and more connectivity options to move healthcare delivery beyond traditional approaches. The product is scheduled for worldwide release in the coming months, the Skaneateles Falls, New York firm said.

You may also be interested in...



Normality Reasserts Itself For Biotech IPOs

The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.

MRM Health Pulls A Pouchitis Hit Out Of The Bag

The mid-stage success is encouraging, but taking on Takeda won’t be easy.

Novartis Draws Out Its APPLAUSE

Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel